These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19749465)

  • 21. Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.
    Radi M; Crespan E; Botta G; Falchi F; Maga G; Manetti F; Corradi V; Mancini M; Santucci MA; Schenone S; Botta M
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1207-11. PubMed ID: 18078752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acid-base profiling of imatinib (gleevec) and its fragments.
    Szakács Z; Béni S; Varga Z; Orfi L; Kéri G; Noszál B
    J Med Chem; 2005 Jan; 48(1):249-55. PubMed ID: 15634018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformational flexibility, binding energy, role of salt bridge and alanine-mutagenesis for c-Abl kinase complex.
    Dubey KD; Ojha RP
    J Mol Model; 2012 May; 18(5):1679-89. PubMed ID: 21811775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.
    Aleksandrov A; Simonson T
    J Biol Chem; 2010 Apr; 285(18):13807-15. PubMed ID: 20200154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex.
    Jacobs MD; Caron PR; Hare BJ
    Proteins; 2008 Mar; 70(4):1451-60. PubMed ID: 17910071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.
    Gambacorti-Passerini C; Gasser M; Ahmed S; Assouline S; Scapozza L
    Leukemia; 2005 Jul; 19(7):1267-9. PubMed ID: 15858616
    [No Abstract]   [Full Text] [Related]  

  • 27. Molecular interactions in imatinib-DPPC liposomes.
    Béni S; Budai M; Noszál B; Gróf P
    Eur J Pharm Sci; 2006 Feb; 27(2-3):205-11. PubMed ID: 16289747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K; Matsumoto T; Hirota S
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Energetic dissection of Gleevec's selectivity toward human tyrosine kinases.
    Agafonov RV; Wilson C; Otten R; Buosi V; Kern D
    Nat Struct Mol Biol; 2014 Oct; 21(10):848-53. PubMed ID: 25218445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
    Mukherjee J; Kamnasaran D; Balasubramaniam A; Radovanovic I; Zadeh G; Kiehl TR; Guha A
    Cancer Res; 2009 Jun; 69(12):5099-107. PubMed ID: 19509233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
    Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
    Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of the interaction surface for the c-Src-imatinib complex by a molecular dicing technique.
    Wiwanitkit V
    Asian Pac J Cancer Prev; 2007; 8(3):436-7. PubMed ID: 18159983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation.
    Lovera S; Sutto L; Boubeva R; Scapozza L; Dölker N; Gervasio FL
    J Am Chem Soc; 2012 Feb; 134(5):2496-9. PubMed ID: 22280319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Taming the induced folding of drug-targeted kinases.
    Fernández A; Bazán S; Chen J
    Trends Pharmacol Sci; 2009 Feb; 30(2):66-71. PubMed ID: 19097649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-world networks of residue interactions in the Abl kinase complexes with cancer drugs: topology of allosteric communication pathways can determine drug resistance effects.
    Tse A; Verkhivker GM
    Mol Biosyst; 2015 Jul; 11(7):2082-95. PubMed ID: 25996455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. c-Abl is involved in the F-actin assembly triggered by L-selectin crosslinking.
    Chen C; Ba X; Xu T; Cui L; Hao S; Zeng X
    J Biochem; 2006 Aug; 140(2):229-35. PubMed ID: 16840500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small molecule recognition of c-Src via the Imatinib-binding conformation.
    Dar AC; Lopez MS; Shokat KM
    Chem Biol; 2008 Oct; 15(10):1015-22. PubMed ID: 18940662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ONIOM DFT/PM3 calculation on the interaction between STI-571 and abelson tyrosine kinase.
    Xiong YZ; Chen PY
    J Mol Model; 2008 Nov; 14(11):1083-6. PubMed ID: 18663490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of binding mode of imatinib to human α1-acid glycoprotein.
    Fitos I; Simon Á; Zsila F; Mády G; Bencsura Á; Varga Z; Orfi L; Kéri G; Visy J
    Int J Biol Macromol; 2012 Apr; 50(3):788-95. PubMed ID: 22142793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.
    Geoerger B; Morland B; Ndiaye A; Doz F; Kalifa G; Geoffray A; Pichon F; Frappaz D; Chatelut E; Opolon P; Hain S; Boderet F; Bosq J; Emile JF; Le Deley MC; Capdeville R; Vassal G;
    Eur J Cancer; 2009 Sep; 45(13):2342-51. PubMed ID: 19362466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.